Emazid 25 MG


Emazid 25 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)


Indications of Emazid 25 Tablet

Empagliflozin is used to improve glycemic control in persons with type 2 diabetes mellitus as a supplement to diet and exercise.

In adult patients with type 2 diabetes mellitus with established cardiovascular disease, the goal is to lower the risk of cardiovascular death.


Pharmacology of Emazid 25 Tablet

Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2). The SGLT2 co-transporters in the kidney are responsible for glucose reabsorption from the glomerular filtrate. SGLT2 inhibition has a glucuretic action, which inhibits renal absorption and lowers the renal glucose threshold, leading in higher glucose excretion. It also helps with weight loss and lowers blood pressure, as well as lowering hyperglycemia.


Dosage and Administration of Emazid 25 Tablet

The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.


Interaction of Emazid 25 Tablet

Empagliflozin co-administration with diuretics resulted in increased urine volume.

Insulin or Insulin Secretagogues: Taking Empagliflozin together with insulin or insulin secretagogues raises the risk of hypoglycemia.

Positive Urine Glucose Test: In patients on SGLT2 inhibitors, monitoring glycemic control with urine glucose tests is not suggested since SGLT2 inhibitors enhance urinary glucose excretion, resulting in positive urine glucose tests. Use different strategies to keep track of your glycemic control.

1,5-anhydroglucitol Interference (1,5-AG) Test: Using the 1,5-AG assay to monitor glycemic control is not suggested since 1,5-AG readings are inaccurate in measuring glycemic control in patients using SGLT2 inhibitors. Use different strategies to keep track of your glycemic control.



Patients having a history of serious allergic reactions to Empagliflozin or any of its constituents, severe renal impairment, end-stage renal disease, or dialysis should not take Empagliflozin.


Side effects of Emazid 25 Tablet

Urinary tract infections and female genital mycotic infections are the most common side effects related with Empagliflozin. Dehydration, hypotension, weakness, disorientation, and increased thirst are all typical side effects.


Pregnancy & Lactation

Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiated in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.


Precautions & Warnings

Empagliflozin has not been studied in pregnant women in a sufficient and well-controlled manner. Only if the possible benefit outweighs the risk to the fetus should empagliflozin be used during pregnancy. Empagliflozin is not known to be excreted in human milk. It’s not a good idea to do it if you’re breastfeeding.


Therapeutic Class

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors


Storage Conditions

Keep away from light and moisture in a cool, dry location (below 30° C). Keep out of children’s reach.


Pharmaceutical Name of Emazid 25 Tablet

Eskayef Pharmaceuticals Ltd

Generic of Emazid 25 Tablet